A1CZ8

(1P,4'P)-3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-2'-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one

Created:	2025-11-09
Last modified:	2026-11-11

Find Related PDB Entry
1 entries where A1CZ8 is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	58
Chiral Atom Count	0
Bond Count	61
Aromatic Bond Count	18

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(1P,4'P)-3-chloro-4-[(3,5-difluoropyridin-2-yl)methoxy]-2'-[2-(2-hydroxypropan-2-yl)pyrimidin-4-yl]-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one
Systematic Name (OpenEye OEToolkits)	4-[[3,5-bis(fluoranyl)pyridin-2-yl]methoxy]-3-chloranyl-6-methyl-1-[5-methyl-2-[2-(2-oxidanylpropan-2-yl)pyrimidin-4-yl]pyridin-4-yl]pyridin-2-one
Formula	C₂₅ H₂₂ Cl F₂ N₅ O₃
Molecular Weight	513.924
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	14.52	CC(C)(O)c1nccc(n1)c1cc(c(C)cn1)N1C(C)=CC(OCc2ncc(F)cc2F)=C(Cl)C1=O
SMILES	CACTVS	3.385	CC1=CC(=C(Cl)C(=O)N1c2cc(ncc2C)c3ccnc(n3)C(C)(C)O)OCc4ncc(F)cc4F
SMILES	OpenEye OEToolkits	3.1.0.0	Cc1cnc(cc1N2C(=CC(=C(C2=O)Cl)OCc3c(cc(cn3)F)F)C)c4ccnc(n4)C(C)(C)O
Canonical SMILES	CACTVS	3.385	CC1=CC(=C(Cl)C(=O)N1c2cc(ncc2C)c3ccnc(n3)C(C)(C)O)OCc4ncc(F)cc4F
Canonical SMILES	OpenEye OEToolkits	3.1.0.0	Cc1cnc(cc1N2C(=CC(=C(C2=O)Cl)OCc3c(cc(cn3)F)F)C)c4ccnc(n4)C(C)(C)O
InChI	InChI	1.06	InChI=1S/C25H22ClF2N5O3/c1-13-10-30-18(17-5-6-29-24(32-17)25(3,4)35)9-20(13)33-14(2)7-21(22(26)23(33)34)36-12-19-16(28)8-15(27)11-31-19/h5-11,35H,12H2,1-4H3
InChIKey	InChI	1.06	FQPQMJULRZINPV-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB16502
Name	Zunsemetinib
Groups	investigational
Description	ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. Additionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.
Synonyms	Zunsemetinib (2′S)-3-Chloro-4-[(3,5-difluoro-2-pyridinyl)methoxy]-2′-[2-(1-hydroxy-1-methylethyl)-4-pyrimidinyl]-5′,6-dimethyl[1(2H),4′-bipyridin]-2-one (P)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2'-(2-(2-hydroxypropan-2-yl)pyrimidin-4yl)-5',6-dimethyl-2H-[1,4'-bipyridin]-2-one
Categories	Experimental Unapproved Treatments for COVID-19
CAS number	1640282-42-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
MAP kinase-activated protein kinase 2	MLSNSQGQSPPVPFPAPAPPPQPPTPALPHPPAQPPPPPPQQFPQFHVKS...	unknown	inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682